RDR Alert®

Investigators conducted an extensive literature review on clinical COVID-19 outcomes in patients with SCD or SCT to better navigate treatment during the pandemic.

Regina Hartfield is the new CEO and president of the Sickle Cell Association of America. Listen to our interview with her to find out what's in store for 2022.

Baez-Sosa explains why further investigation of alloimmunization in patients with sickle cell disease is crucial.

Exciting new therapies for sickle cell disease are on the horizon. We explored some of the most promising investigational therapies in recognition of National Blood Donor Month.

Beach shares about Haywood's life, research, and impact on the sickle cell disease community after working alongside him at Johns Hopkins School of Medicine.

Achebe explains the promising results of the open label extension to the HOPE trial for patients with sickle cell disease.

Phase 3 trial examines if adjusting the dose of hydroxyurea reduces the risk of stroke in children with sickle cell anemia.

Accurate results can be obtained rapidly with this intuitive whole blood hemostasis system, allowing for efficient workflow at the point of care.

In this interview, Valton details the editing function of TALGlobin01 and how it stands out among traditional gene therapy approaches to sickle cell disease.

Björn Mellgård gets technical as he describes the function of TAK-755, the recombinant ADAMTS13 enzyme, in sickle cell disease and cTTP.

Investigators developed the first module to confront implicit bias toward patients with sickle cell disease on an individual or personal level.

The American Society of Hematology debuted its Health Equity Rounds series, which are interactive, case-based discussions with an interdisciplinary panel to include hematologists, health equity/public health experts, patients, and patient advocates.

The clinical program has been suspended for patients that are under the age of 18 after an adolescent patient developed persistent anemia.

Fuad El Rassi talks about the Grady Comprehensive Sickle Cell center, the COVID-19 vaccine, and the data he presented at ASH.

The treatment represents the first approved treatment that directly targets sickle hemoglobin polymerization.

Findings from the SWAY trial highlight a pressing need for varying and more personalized treatment methods for patients.

TAK-755, a recombinant ADAMTS13, is examined for its therapeutic benefit to patients with sickle cell disease and patients with cTTP.

The treatment resulted in a significant reduction of proteinuria from baseline in 34% of trial participants.

The approval represents the first ever treatment for the disease in patients aged 2 years and older.

The enrollment distribution was consistent by ethnicity over the course of 18 years, with no change in diversity over time despite there being an increase in the UK in the minority population.

Of the SCD patients who contracted COVID-19, 49% of them visited the Grady Comprehensive Sickle Cell center because of a vaso-occlusive event.

Data show patients with sickle cell disease identified by distinct cognitive profile should have neurorehabilitation tailored to each unique profile.

After 2 months of voxelotor treatment, all patients with sickle cell anemia perceived global improvement, but peak VO2 did not change in 8 of 9 patients.

Data show most patients (60.3%) with sickle cell disease achieved a Hb increase of >1 g/dL during the follow-up period.

Patients with SCD were not at an increased risk of death or disease complications.